Skip to main content
NewslettersWatchlist

Clearpoint Neuro Inc(CLPT-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy

Globe Newswire - Wed Jun 29, 2022

SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patient in their Phase 1/2 clinical trial of its lead program NRTX-1001, in a first-in-human epilepsy study. Harish Babu, MD, PhD, Assistant Professor of Neurosurgery at SUNY Upstate Medical University administered the first dose.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter
A look at how people are using the best all-around investing product. Plus, top stock picks from our new Readers’ Portfolio
ETF or Exchange Traded Fund text on black block
market news
The close: Month-end repositioning spurs late-day stock rally
Trader Anthony Confusione works on the floor of the New York Stock Exchange, Thursday, May 30.
alternative investments
Why this money manager thinks investors should get off the sidelines but still be defensive
Illustration of Chris Kerlow for The Mover. June 23/24, 2023. Illustration by Joel Kimmel
globe advisor weekly newsletter
Canadian investors are ‘underserved’ in alternative investments and private capital
Investors want greater clarity from their advisors around what RI means and how it can fit their portfolios.
alternative investments
Why rising interest in traditional fixed income is not affecting alternatives
A man looks up as he leans a red ladder against a tall stack of coins that is topped with an interest rate symbol.
alternative investments
Fund houses buy up ‘alts’ specialists to move beyond equities and bonds
FILE PHOTO: Larry Fink, Chief Executive Officer of BlackRock, takes part in the Yahoo Finance All Markets Summit in New York, U.S., February 8, 2017. REUTERS/Lucas Jackson
opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza
alternative investments
Four ways to create more diversified and resilient portfolios
One of a set. Graphic Arrow on abstract background.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).